Abstract:Background The inflammatory biomarker YKL‐40 has previously been studied as a potential risk marker in cardiovascular disease. We aimed to assess the prognostic reclassification potential of serum YKL‐40 in patients with stable coronary artery disease. Methods and Results The main study population was the placebo group of the CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) trial. The primary outcome was a composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all‐cause mortality. We used Cox proportional hazards regression models adjusted for C‐reactive protein level and baseline cardiovascular risk factors. Improvement in prediction by adding serum YKL‐40 to the risk factors was calculated using the Cox‐Breslow method and c‐statistic. A total of 2200 patients were randomized to placebo, with a follow‐up duration of 10 years. YKL‐40 was associated with an increased risk of the composite outcome (hazard ratio per unit increase in (YKL‐40) 1.13, 95% CI 1.03–1.24, P =0.013) and all‐cause mortality (hazard ratio 1.32, 95% CI 1.17–1.49, P <0.0001). Considering whether a composite‐outcome event was more likely to have, or not have, occurred to date, we found 68.4% of such predictions to be correct when based on the standard predictors, and 68.5% when serum YKL‐40 was added as a predictor. Equivalent results were obtained with c‐statistics. Conclusions Higher serum YKL‐40 was independently associated with an increased risk of adverse cardiovascular outcomes and mortality. Addition of YKL‐40 did not improve risk prediction in patients with stable coronary artery disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT00121550. Clinical Perspective What Is New? In patients with stable coronary artery disease, higher YKL‐40 is significantly related to cardiovascular events and mortality over 10 years of follow‐up after adjustment for standard predictors and high‐sensitivity C‐reactive protein, possibly reflecting high‐risk atherosclerotic progression and inflammation. What Are the Clinical Implications? In reclassification analysis YKL‐40 did not improve prognostic accuracy compared with predictions based only on standard predictors, and the value of measuring YKL‐40 to support clinical decision making appears limited. Introduction The desire to better assess prognosis in patients with cardiovascular disease (CVD) and further advance the understanding of the underlying atherosclerotic process has prompted the emergence of numerous potential CVD biomarkers. Many candidates have demonstrated consistent association with standard CVD outcome measures. Nonetheless, auxiliary predictive potential in addition to that offered by standard available clinical characteristics is in many cases absent or unclear, hindering translation of results into specific changes in patient management strategies. 1 , 2 , 3 However, in addition to possible utility in risk prediction, biomarker studies may unravel new key factors in CVD pathogenesis such as proinflammatory effectors, and ultimately help identify new potential upstream treatment targets. 4 , 5 YKL‐40, also known as chitinase‐3‐like‐1, is an inflammatory biomarker which has gathered increasing evidence during the past 2 decades. 6 It is considered an acute‐phase protein and has been specifically linked to the inflammatory process in the atherosclerotic plaque, 7 diseases of extracellular remodeling and fibrosis, 8 angiogenesis and regulation of proinflammatory cascades. 9 , 10 YKL‐40 has recently been associated with development of hyperlipidemia and ischemic stroke in a study of almost 10 -Abstract Truncated-

YKL-40 Aggravates Early-Stage Atherosclerosis by Inhibiting Macrophage Apoptosis in an Aven-dependent Way

YKL-40 Promotes the Progress of Atherosclerosis Independent of Lipid Metabolism in Apolipoprotein E−/− Mice Fed a High-Fat Diet

Abstract 4142693: Deletion of Prekallikrein Enhances Atherosclerotic Plaque Stability and Prevents Plaque Rupture by Modulating Macrophages and Smooth Muscle Cells

Macrophage K63-Linked Ubiquitination of YAP Promotes Its Nuclear Localization and Exacerbates Atherosclerosis

K-80003 Inhibition of Macrophage Apoptosis and Necrotic Core Development in Atherosclerotic Vulnerable Plaques.

Low-Density Lipoprotein Receptor–Related Protein 1 Prevents Early Atherosclerosis by Limiting Lesional Apoptosis and Inflammatory Ly-6C <sup>high</sup> Monocytosis

Stage-Dependent Impact of RIPK1 Inhibition on Atherogenesis: Dual Effects on Inflammation and Foam Cell Dynamics

Selective Inhibition Of Pi3k/Akt/Mtor Signaling Pathway Regulates Autophagy Of Macrophage And Vulnerability Of Atherosclerotic Plaque

Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

YKL-40 Is Associated With Ultrasound-Determined Carotid Atherosclerotic Plaque Instability

Macrophage Apoptosis and Efferocytosis in the Pathogenesis of Atherosclerosis

Apoptosis Signal–Regulating Kinase 1 Deficiency Accelerates Hyperlipidemia-Induced Atheromatous Plaques Via Suppression of Macrophage Apoptosis

Macrophages Promote Atherosclerosis Development by Inhibiting CD8T Cell Apoptosis

Apigenin Inhibits Macrophage Pyroptosis Through Regulation of Oxidative Stress and the NF-B Pathway and Ameliorates Atherosclerosis

Silencing of Junctional Adhesion Molecule-Like Protein Attenuates Atherogenesis and Enhances Plaque Stability in ApoE Mice.

The Atheroprotective Role of Lipoxin A4 Prevents Oxldl-Induced Apoptotic Signaling in Macrophages Via JNK Pathway.

Macrophages overexpressing interleukin-10 target and prevent atherosclerosis: regression of plaque formation and reduction in necrotic core

Low-Density Lipoprotein Receptor-Related Protein 1 Prevents Early Atherosclerosis By Limiting Lesional Apoptosis And Inflammatory Ly-6c(High) Monocytosis Evidence That The Effects Are Not Apolipoprotein E Dependent

Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets

Ag1296 Enhances Plaque Stability Via Inhibiting Inflammatory Responses and Decreasing Mmp-2 and Mmp-9 Expression in Apoe-/- Mice

Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in macrophages to reduce atherosclerosis in ApoE-/- mice